Table 2.
Relationship between SP expression and clinicopathological features of breast cancer patients with HR-ve versus HR + ve tumors
| Parameters | HR-ve (n = 77) |
HR + ve (n = 67) |
||||
|---|---|---|---|---|---|---|
| Low SP | High SP | p-value | Low SP | High SP | p-value | |
| Age (Years) | 51.77 ± 12.97 | 49.97 ± 10.76 | 0.529 | 52.26 ± 12.50 | 52.21 ± 8.95 | 0.984 |
|
Tumor grade I II III |
0 (0) 7 (14.9) 40 (85.1) |
0 (0) 4 (13.3) 26 (86.7) |
1.000 |
4 (10.5) 13 (34.2) 21 (55.3) |
3 (10.3) 11 (37.9) 15 (51.7) |
0.936 |
| Tumor volume (cm 3 ) | 62.28 ± 105.25 | 34.85 ± 47.08 | 0.184 | 33.53 ± 47.53 | 22.67 ± 30.91 | 0.289 |
|
TNM Stage I II III IV |
3 (6.5) 16 (34.8) 16 (34.8) 11 (23.9) |
1 (3.4) 3 (10.3) 12 (41.4) 13 (44.8) |
0.056 |
1 (2.6) 9 (23.7) 11 (28.9) 17 (44.7) |
2 (7.1) 9 (32.1) 9 (32.1) 8 (28.6) |
0.527 |
|
TNM stage I/II III/IV |
19 (41.3) 27 (58.7) |
4 (13.8) 25 (86.2) |
0.020 |
10 (26.3) 28 (73.7) |
11 (39.3) 17 (60.7) |
0.295 |
|
T stage T1 T2 T3 T4 |
3 (6.4) 28 (59.6) 12 (25.5) 4 (8.5) |
3 (10.0) 9 (30.0) 13 (43.3) 5 (16.7) |
0.081 |
3 (7.9) 19 (50.0) 11 (28.9) 5 (13.2) |
2 (6.9) 18 (62.1) 8 (27.6) 1 (3.4) |
0.569 |
|
pT T1/T2 T3/T4 |
31 (72.1) 16 (47.1) |
12 (27.9) 18 (52.9) |
0.035 |
22 (52.4) 16 (64.0) |
20 (47.6) 9 (36.0) |
0.447 |
|
N stage N0 N1 N2 N3 |
18 (39.1) 7 (15.2) 12 (26.1) 9 (19.6) |
2 (7.1) 8 (28.6) 4 (14.3) 14 (50.0) |
0.002 |
12 (32.4) 6 (16.2) 8 (21.6) 11 (29.7) |
8 (28.6) 10 (35.7) 5 (17.9) 5 (17.9) |
0.332 |
|
M stage M0 M1 |
35 (76.1) 11 (23.9) |
16 (55.2) 13 (44.8) |
0.077 |
21 (55.3) 17 (44.7) |
20 (71.4) 8 (28.6) |
0.208 |
|
Axillary lymph nodes metastasis Negative Positive |
18 (39.1) 28 (60.9) |
2 (6.9) 27 (93.1) |
0.003 |
12 (31.6) 26 (68.4) |
9 (31.0) 20 (69.0) |
1.000 |
|
Lymphatic/vascular invasion Negative Positive |
18 (41.9) 25 (58.1) |
6 (20.7) 23 (79.3) |
0.077 |
12 (31.6) 26 (28.4) |
11 (39.3) 17 (60.7) |
0.604 |
|
HER2 status Negative Positive |
24 (51.1) 23 (48.9) |
11 (36.7) 19 (63.3) |
0.248 |
11 (28.9) 27 (71.1) |
20 (69.0) 9 (31.0) |
0.001 |
|
DCIS Absent Present |
16 (36.4) 28 (63.6) |
6 (20.0) 24 (80.0) |
0.195 |
7 (18.4) 31 (81.6) |
3 (10.3) 26 (89.7) |
0.495 |
|
Family History No Yes |
28 (80.0) 7 (20.0) |
11 (61.1) 7 (38.9) |
0.191 |
28 (84.8) 5 (15.2) |
23 (79.3) 6 (20.7) |
0.741 |
|
Ki-67 Low High |
21 (44.7) 26 (55.3) |
14 (46.7) 16 (53.3) |
1.000 |
28 (73.7) 10 (26.3) |
20 (69.0) 9 (31.0) |
0.786 |
|
NK1R Low High |
33 (70.2) 14 (29.8) |
12 (40.0) 18 (60.0) |
0.010 |
24 (63.2) 14 (68.8) |
22 (75.9) 7 (24.1) |
0.300 |
|
PKM2 Low High |
24 (58.5) 17 (41.5) |
18 (69.2) 8 (30.8) |
0.444 |
26 (68.4) 12 (31.6) |
10 (35.7) 18 (64.3) |
0.012 |
HR: hormone receptor, HER2: human epidermal growth factor receptor 2, DCIS: ductal carcinoma in situ, SP: substance P, NK1R: neurokinin 1 receptor, PKM2: pyruvate kinase M2